Benefit-Risk Management

ONLY 1 OFFERING IN 2017! Our best-in-class instructors teach you the Do’s and Don’ts for BRM over the lifecycle of the product, and the course includes the Rev 2 of the GVP Modules V and XVI.

Back to Agenda

SESSION 9: EVALUATION OF RISK MINIMISATION EFFECTIVENESS

Session Chair(s)

Michael Forstner, PhD, MPH, MSc

Managing Director, Head of Pharmacoepidemiology Practice

Mesa Laubela-Consulting, Switzerland

Tools and methodologies available
Levels of metrics
Required evaluation levels and examples of satisfactory results

Speaker(s)

EVALUATION OF RISK MINIMISATION EFFECTIVENESS

Michael Forstner, PhD, MPH, MSc

Mesa Laubela-Consulting, Switzerland

Managing Director, Head of Pharmacoepidemiology Practice

Have an account?

Benefit-Risk Management

SESSION 9: EVALUATION OF RISK MINIMISATION EFFECTIVENESS

Session Chair(s)

Michael Forstner, PhD, MPH, MSc

Speaker(s)

EVALUATION OF RISK MINIMISATION EFFECTIVENESS

Be informed and stay engaged.